瑞莎珠单抗治疗克罗恩病的长期结局:一项真实世界GETAID研究
该研究回顾性纳入25个GETAID中心2021年5月至2023年8月连续接受瑞莎珠单抗治疗的174例克罗恩病患者,评估长期有效性与安全性。第52周无激素临床缓解率为46%(58/125),临床缓解率为48%(60/125),药物持续率为79%,安全性特征与文献一致。
要点
- 第52周无激素临床缓解率为46%(58/125),临床缓解率为48%(60/125)。
- 瑞莎珠单抗持续率在第12、26、52周分别为94%、89%、79%。
- 45例(26%)停药,36例(20.9%)住院,22例(12.6%)需肠切除。
核心结论
- 这是首个报告瑞莎珠单抗治疗难治性克罗恩病长期结局的真实世界研究,约半数患者1年后达到无激素临床缓解,安全性特征与文献一致。
研究设计与样本
- 回顾性纳入2021年5月至2023年8月在25个GETAID中心连续接受瑞莎珠单抗治疗的克罗恩病患者174例。
- 主要终点为第52周无激素临床缓解(Harvey Bradshaw指数<5)。
主要发现
- 174例患者中,99%、93%、96%分别曾暴露于抗TNF、维得利珠单抗、乌司奴单抗,所有患者均接受过≥3种生物制剂,108例(62%)有既往肠切除史。
- 第26周无激素临床缓解率为47%(72/152),临床缓解率为52%(79/152);第52周分别为46%(58/125)和48%(60/125)。
- 瑞莎珠单抗持续率在第12、26、52周分别为94%、89%、79%。
- 随访结束时45例(45/174;26%)停药,原因包括失应答42%、原发失败37%、不耐受13%;36例(36/174;20.9%)住院,22例(22/174;12.6%)需肠切除。
- 51例(29%)发生不良事件,其中26例(15%)为严重不良事件(克罗恩病 flare n=17);观察到1例死亡(心肌梗死)和1例癌症(甲状腺乳头状癌)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD). METHODS: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks. RESULTS: Of the 174 patients included, 99%, 93%, and 96% had been previously exposed to anti-TNF, vedolizumab, and ustekinumab, respectively. All patients had received ≥3 biologics, and 108 (62%) had previous intestinal resection. Median follow-up was 13.7 months (interquartile range, 10.0-18.1 months). The rates of steroid-free clinical remission and clinical remission at week 26 were 47% (72/152) and 52% (79/152), and 46% (58/125), and 48% (60/125) at week 52, respectively. Risankizumab persistence rates were 94%, 89%, and 79% at weeks 12, 26, and 52, respectively. At the end of follow-up, 45 (45/174; 26%) patients had discontinued risankizumab (loss of response, 42%; primary failure, 37%; intolerance, 13%). Thirty-six patients (36/174; 20.9%) were hospitalized, and 22 (22/174; 12.6%) required intestinal resection. Fifty-one patients (29%) had an adverse event, including 26 (15%) serious adverse events (CD flare, n = 17). One death (myocardial infarction) and one cancer (papillary thyroid carcinoma) were observed. CONCLUSION: This is the first real-life study to report long-term outcomes in patients with refractory CD treated with risankizumab. One-half of the patients achieved steroid-free clinical remission after 1 year, and the safety profile was consistent with the literature.
引用
- Fumery M, Caron B, Hébuterne X, et al. Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study. Clin Gastroenterol Hepatol. 2024. PMID: 38729389. doi:10.1016/j.cgh.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。